Development of multidrug-resistance convertors: Sense or nonsense?

Investigational New Drugs

Volumn 18, Issue 3, 2000, Pages 205-220

  Van Zuylen, Lia ^a   Nooter, Kees ^a   Sparreboom, Alex ^a   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cancer; MDR convertors; MRP; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; BIRICODAR; CYCLOSPORIN A; DEXVERAPAMIL; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; GLYCOPROTEIN P; LANIQUIDAR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; QUININE; VALSPODAR; VERAPAMIL;

CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0033873755     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006487003814     Document Type: Review

References (151)

1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152-162, 1976
2. Sharom, FJ: The P-glycoprotein efflux pump: how does it transport drugs? J Membr Biol 160: 161-175, 1997
3. Gottesman, MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrag transporter. Annu Rev Biochem 62: 385-427, 1993
4. Twentyman PR: Transport proteins in drug resistance: biology and approaches to circumvention. J Intern Med 242: 133-137, 1997
5. Germann UA: P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A: 927-944, 1996
6. Higgins CF, Gottesman MM: Is the multidrag transporter a flippase? Trends Biochem Sci 17: 18-21, 1992
7. Zhu BT: A novel hypothesis for the mechanism of action of P-glycoprotein as a multidrug transporter. Mol Carcinog 25: 1-13, 1999
8. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287, 1990
9. Chaudhary PM, Roninson IB: Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66: 85-94, 1991
10. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber J, Andreeff M: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80: 2729-2734, 1992
11. Schinkel AH, Smit JJ, van Teffingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994
12. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, van Deemter L, Smit JJM, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JMJM, Fibbe WE, Borst P: Normal viability and altered pharmacokinetics in mice lacking mdr1-typs (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033, 1997
13. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJM, Borst P: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31 A: 1295-1298, 1995
14. Lankas GR, Cartwright ME, Umbenhauer D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxic Appl Pharmacol 143: 357-365, 1997
15. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992
16. Cole SPC, Sparks KE, Eraser K, Loe DW, Grant CE, Wilson GM, Deeley RG: Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994
17. Vanhoefer U, Cao S, Harstrick A, Seeber S, Rusturn YM: Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP). Ann Oncol 8: 1221-1228, 1997
18. Jedlitschky G, Leier I, Buchholz U, Center M, Keppler D: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833-4836, 1994
19. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D: Transport of glutathione, glucoronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996
20. Barnouin K, Leier I, Jedlitschky G, Pourtier-Manzanedo A, König J, Lehmann WD, Keppler D: Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione. Br J Cancer 77: 201-209, 1998
21. 4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247: 859-863, 1998
22. Zaman GJ, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RP, Baas F, Borst: Role of glutathione in the export of compounds from protein. Prot Natl Acid Sci USA 92: 7690-7694, 1995
23. r 190,000 multidrug resistance protein (MRP). Evidence for cotransport with reduced glutathione. Cancer Res 58: 5130-5136, 1998
24. Ishikawa T, Bao JJ, Yamana Y, Akimaru K, Frindrich K, Wright CD, Kuo MT: Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271: 14981-14988, 1996
25. Roelofsen H, Vos TA, Schippers IJ, Kuipers F, Koning H, Moshage H, Jansen PLM, Muller M: Increased levels of the multidrug resistance protein in lateral membranes of proliferating hepatocyte-derived cells. Gastroenterology 112: 511-521, 1997
26. Evers R, Zaman GJR, van Deemster L, Jansen H, Calafat J, Oomen LCJM, Oude Elferink RPJ, Borst P, Schinkel AH: Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest 97: 1211-1218, 1996
27. Wijnholds J, Scheffer GL, van der Valk M, van der Valk P, Beijnen JH, Scheper FJ, Borst P: Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med 188 (5): 397-808, 1998
28. Nooter K, Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract 192: 768-780, 1996
29. Loe DW, Deeley RG, Cole SPC: Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A: 945-957, 1996
30. Deeley RG, Cole SPC: Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8: 193-204, 1997
31. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P, Borst P: Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3: 1275-1279, 1997
32. Rappa G, Lorico A, Flavelli RA, Sartorelli AC: Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57: 5232-5237, 1997
33. Nooter K, Herweijer H: Multidrug resistance (mdr) genes in human cancer. Br J Cancer 63: 663-669, 1991
34. Hotta T. Tanimura H, Tsunoda T, Iwahashi M, Tani M, Noguchi K, Mizobata S, Arii K, Terasawa H, Nakamori M, Yamaue H: P-glycoprotein expression and chemosensitivity in highly purified fresh human gastrointestinal cancer cells. Hepatogastroenterology 46: 316-321, 1999
35. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231-1237, 1996
36. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto H: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54: 1355-1359, 1994
37. Kavallaris M, Leary JA, Barrett JA, Friedlander ML: MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 102: 7-16, 1996
38. Chan HS, Haddad G, Thomer PS, DeBoer G, Lin YR Ondrusek N, Yeger H, Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991
39. Abe T, Mori T, Wakabayashi Y, Nakagawa M, Cole SPC, Koike K, Kuwano M, Hori S: Expression of multidrug resistance protein gene in patients with gborna after chemotherapy. J Neuro-Oncol 40: 11-18, 1998
40. Stein U, Walther W, Wunderlich V: Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur J Cancer 10: 1541-1545, 1994
41. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowske A, Roessner A: Expression of multidrug-resistance protein gene in human soft-tissue sarcomas. J Cancer Res Clin Oncol 122: 161-165, 1996
42. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Wahrer DC, Ossenkoppele GJ, Schuurhuis GJ: Theoretical and practical considerations for the measurement of P- glycoprotein function in acute myeloid leukemia. Leukemia 11: 1110-1118, 1997
43. Webb M, Brun M, McNiven M, Le Couteur D, Craft P: MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders. Br J Haematol 102: 710-717, 1998
44. Hokmayer TA, Hilsenbeck S, Von Hoff DD, Roninson IB: Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84: 1486-1491, 1992
45. Willman CL: The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34: 25-33, 1997
46. Leith C, Kopecky K, Godwin J, McConnell T, Slovak ML, Chen 1-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89: 3323-3329, 1997
47. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB, Coon JS: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991
48. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphocytic leukemia cells at diagnosis. Blood 79: 473-476, 1992
49. Goasguen JE, Dossot J-M, Fardel O, Le Mee F, Le Gall E, Leblay R, LePrise PY, Chaperon J, Fauchet R: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394-2398, 1993
50. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R: P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 8: 974-977, 1994
51. Guerci A, Merlin JL, Missourn N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and p-glycoprotein expression simultaneously determined by flow cytometry. Blood 85: 2147-2153, 1995
52. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, Serra M: Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385, 1995
53. Chin K-V, Kazumitsu U, Pastan 1, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255: 459-462, 1992
54. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM: Expression of the multidrug-resistant gene in hepatocarcinogenesis and regenerating rat liver. Science 236: 1120-1122, 1987
55. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E: N-glycosylation and deletion mutants of the human mdr1 P-glycoprotein. J Biol Chem 268: 7474-7481, 1993
56. Nooter K, Westerman AM, Flens MJ, Zaman, GJR, Scheper, RJ, Van Wingerden KE, Burger, H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT, Stoter G: Expression of the multidrug resistanceassociated (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310, 1995
57. Filipits M, Suchomel RW, Dekan G, Stigibauer W, Haider K, Depisch D, Pirker R: Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer 75: 208-212, 1997
58. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486-493, 1997
59. Nooter K, Brutel de la Riviere G, Klijn J, Stoter G, Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885-1886, 1997
60. Nooter K, Kok, T, Bosman FT, van Wingerden KE, Stoter G: Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapy. Eur J Cancer 34: 81-86, 1998
61. Takebayashi Y, Akiyama S, Natsugoe S, Hokita S, Niwa K, Kitazono M, Sumizawa T, Tani A, Furukawa T, Aikou T: The expression of muffidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82: 661-666, 1998
62. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N, Nakamura M: Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72: 550-554, 1995
63. Narasaki F, Matsuo I, Ikuno N, Fukuda M, Soda H, Oka M: Multidrug resistanceassociated protein (MRP) gene expression in human lung cancer. Anticancer Res 16: 2079-2082, 1996
64. Nooter K, Bosman FT, Burger H, van Wingerden KE, Flens MJ, Scheper RJ, Oostrum RG, Boersma AWM, van der Gaast A, Stoter G. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. Ann Oncol 7: 75-81, 1996
65. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SP, Gerlach JH: Expression of the MRP and MDR1 multidrug resistance gene in small cell lung cancer. Clin Cancer Res 3: 115-122, 1997
66. Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M: Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. Int J Cancer 71: 108-115, 1997
67. Burger H, Nooter K, Zaman G.I. Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G: Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 8: 990-997, 1994
68. Burger H, Nooter K, Sonneveld P, van Wingerden KE, Zaman GJ, Stoter G: High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haematol 88: 348-356, 1994
69. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, Haber M: Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231-238, 1996
70. Nooter K, Oostrum R, Jonker R, van Dekken H, Stoikdijk W, van den Engh G: Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry. Cancer Chemother Pharmacol 23: 296-300, 1989
71. Twentyman PR: MDR1 (P-glycoprotein) gene expression -Implications for resistance modifiers trials. J Natl Cancer Inst 84: 1458-1460, 1992
72. Fine RL: Multidrug resistance. Cancer Chemother Biol Response Modif 10: 73-84, 1989
73. Tsuruo T, lida H, Tsukagoshi S, Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981
74. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990
75. Bradshaw DM, Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16 (11): 3674-3690, 1998
76. Advani R, Saba H, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 93: 787-795, 1999
77. Planting AST, van der Gaast A, Sparreboom A, van der Burg MEL, de Boer M, Wissel PS, Jewell RC, Paul EM, Verweij J: Phase I and pharmacokinetic (PK) study targeting a 100 ng/mL plasma concentration of the potent multidrug resistance (MDR) modulator GF120918 (GF) with doxorubicin (dox) in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 199a, 1998 (abstract)
78. Ferry D, Moore M, Bartlett NL, Fyfe D, Oza A, Fracasso PM, Kersey K, Wissel PS, Jewell RC, Paul EM. Phase I and pharmacokinetic study targeting a 500 ng/ml plasma concentration of the potent multidrug resistance modulator GF120918 with doxorubicin in patients with advanced solid tumors. Proc Am Soc Clin Oncol 17: 922, 1998 (abstract)
79. Rowinsky EK, Smith L, Wang Y-M, Chaturvedi P, Vilialona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson Jr J, Harding MW, Von Hoff DD: Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964-2976, 1998
80. Peck RA, Marshall J, Ziessman H, Hewett J, Schmalbach T, Chatuvedi P, Hawkins M: A phase I trial of doxorubicin and VX-710. Proc Am Assoc Cancer Res 37: 165, 1996 (abstract)
81. van Zuylen L, Sparreboom A, van der Gaast A, van der Berg MEL, van Beurden V, Bol CJ, Woestenborghs R, Palmer PA, Verweij J: The orally administered P-glycoprotein inhibitor R101933 does not alter the pharmacokinetics of docetaxel results of a phase I study. Clin Cancer Res 6: 1365-1371, 2000
82. Awada A, Bleiberg H, Gil T, Di Leo A, Geurs F, de Valeriola D, McCabe S, Palmer PA, Woestenborghs R, Bol CJJG, Piccart MJ: Oral R101933, an inhibitor of MDR1 P-glycoprotein does not significantly alter the pharmacokinetics and pharmacodynamics of paclitaxel. Proc Am Ass Cancer Res 40: 4373, 1999 (abstract)
83. Naito M, Tsuruo T: New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833. Cancer Chemother Pharmacol 40: S20-S24, 1997
84. Naito S, Koike K, Ono M, Machida T, Tasaka S, Kiue A, Koga H, Kumazawa J: Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance. Oncol Res 10: 123-132, 1998
85. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt W, Baughman TM, Bumol TF, Starling JJ: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyidibenzosuberane modulator, LY335979. Cancer Res 56: 4171-4179, 1996
86. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H, Charlton P: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595-600, 1999
87. Mistry P, Plumb J, Eccles S, Watson S, Dale I, Ryder H, Box G, Chariton P, Templeton D, Bevan PB: In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance. Br J Cancer 79: 1672-1678, 1999
88. Beck JF, Buchholz F, Ulrich W-R, Boer R, Sanders KH, Niethammer D, Gekeler V: Rhodamine 123 efflux modulation in the presence of low or high serum from CD56+ hematopoietic cells or CD34+ leukemic blasts by B9309-068, a newly designed pyridine derivative. Cancer Lett 129: 157-163, 1998
89. Chen H, Bamberger U, Heckel A, Guo X, Cheng Y: BIBW-22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53: 1974-1977, 1993
90. List AF, Chakos H, Glinsmann-Gibson B, Bamberger U: Reversal of classical and non-P-glycoprotein (PGP)-mediated multidrug resistance (MDR) by BIBW-22. Blood 86: 516a, 1995 (abstract)
91. 4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208: 345-352, 1995
92. Vanhoefer U, Cao S, Minderman H, Tóth K, Scheper RJ, Slovak ML, Rusturn YM: PAK-104P, a pyridine analogue reverses paclitaxel and doxorubicin resistance in cell lines and nude mice bearing xenografts that overexpress the multidrug resistance protein. Clin Cancer Res 2: 369-377, 1996
93. Beketic-Oreskovic L, Duran GE, Chen G, Dumontet C, Sikic BI: Decreased mutation rate for doxorubicin resistance and suppression of mdr1 gene activation by PSC 833. J Natl Cancer Inst 87: 1593-1602, 1995
94. Beck WT, Grogan TM, Wiliman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW Boyett JM, Brophy NA, Broxterman HJ, Chan HSL, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Rimsza L, Roninson IB, Sikic BI, Twentyman PR, Warnke R, Weinstein R: Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020, 1996
95. Dalton WS, Grogan T, Salmon SE: Drug resistance in multiple myeloma. Cancer Res Ther Control 6: 189-190, 1998
96. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994
97. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD: Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995
98. Versantvoort CH, Schuurhuis GJ, Pinedo HM, Eekman CA, Kuiper CM, Lankelma J, Broxterman HJ: Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 68: 939-946
99. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM: Competitive inhibiton by genistein and ATP-dependence of daunorubicin transport in intact MRP over-expressing human small-cell lung cancer cells. Biochem Pharmacol 48: 1129-1136, 1994
100. Versantvoort CHM, Broxterman W, Bagrij T, Scheper RJ, Twentyman PR: Regulation of glutathione of drug transport in multidrug resitant human lung tumour cell lines overexpressing MRP. Br J Cancer 72: 82-89, 1995
101. Zaman GJR, Lankelma J, van Tellingen O, Beijen J, Dekker H, Paulusma C, Oude Sferink RPJ, Baas F, Borst P: Role of glutathione in the export of compounds from cells by the multidrug-resitance-associated protein. Proc Natl Acad Sci USA 92: 7690-7694, 1995
102. Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res 51: 67-72, 1991
103. Lai GM, Moscow JA, Alvarez MG, Fojo AT, Bates SE: Contribution of glutathione and glutathione-dependent enzymes in the reversal of Adriamycin resistance in colon carcinoma cell lines. Int J Cancer 49: 688-695, 1991
104. Ma L, Krishnarnachary N, Center MS: Phosporylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-3343,1995
105. Bertram J, Paifner K, Killian M, Brysch W, Schlingensiepen K-H, Hiddemann W, Kneba M: Reversal of multiple drug resistance in vitro by phosphorothioate olignucleotides and ribozymes. Anticancer Drugs 6: 124-134, 1995
106. Stewart AJ, Canitrot Y, Baracchini E, Dean NK Deeley RG, Cole SPC: Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate olignucleotides. Biochem Pharmacol 51: 461-469, 1996
107. Rubin SC, Finstad CL, Hoskins WJ, Saigo PF, Provencher DM, Federici MG, Hakes TB, Markman M, Reichman BS, Lloyd KO, Lewis JL: Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance. Am J Obstet Gynecol 163: 69-73, 1990
108. Lehnert M, de Giuli R, Kunke K, Emerson S, Dalton WS, Salmon SE: Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer 32A: 862-867, 1996
109. Smith AJ, Mayer U, Schinkel AH, Borst P: Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. J Natl Cancer Inst 90: 1161-1166, 1998
110. Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S: Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alphal-acid glycoprotein. Cancer Res 58: 3248-3253, 1998
111. Tunggal X, Ballinger JR, Tannock IF: Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agent. Int J Cancer 81: 741-747, 1999
112. Relling MV: Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18: 350-356, 1996
113. Fields A, Hochster H, Runowicz C, Speyer J, Goldberg G, Cohen C, Dottino P, Wadler S, Berk G, Gretz H, Mandeli J, Holland J, Letvak L: PSC833: initial results in refractory ovarian cancer patients. Curr Opin Oncol 10: S21, 1998
114. Sonneveld P, Marie JP, Huisman C, Vekhoff A, Schoester M, Faussat AM, van Kapel J, Groenewegen A, Charnick S, Zittoun R, and Löwenberg: Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. Leukemia 10: 1741-1750, 1996
115. Boote DJ, Dennis IF, Twentyrnan PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610-618, 1996
116. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15: 1796-1802, 1997
117. Giaccone G, Linn SC, Welink J, Catimel G, Stieltjes H, van der Vijgh WJF, Eeltink C, Vermerken JB, Pinedo HM: A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 3: 2005-2015, 1997
118. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon SE, Futcher B, Baier M, Dalton W: Phase I/II trial of cyclosporin as a chemotherapy resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660, 1993
119. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI: Phase I trial of doxorubicin with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 12: 835-842, 1994
120. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI: A phase I trial of etoposide with cyclosporin as a modulator of multidrug resistance. J Clin Oncol 10: 1624-1634, 1992
121. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P: Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53: 4837-4842, 1993
122. Pinedo HM, Giaccone G: P-glycoprotein - a marker of cancer-cell behavior. N Engl J Med 333: 1417-1419, 1995 (editorial)
123. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJT, Juijn JA, Baas F, Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997
124. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415-424, 1989
125. Dalton WS, Crowley JJ, Salmon S, Grogan TM, Laufman LR, Weiss G, Bonnet JD: A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patient with refractory myeloma: A Southwest Oncology Group Study. Cancer 75: 815-820, 1995
126. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K: Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259, 1992
127. Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM: Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group pilot Study. Cancer 85: 358-367, 1999
128. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn J-Y, Sadoun A, Pignon B, Berthou C, Maloisel F, Guyotat D, Casassus P, Ifrah N, Lamy Y, Audhuy B, Colombat P, Harousseau J-L: Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: A randomized multicenter study. Blood 88: 1198-1205, 1996
129. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE: P-glycoprotein expression in malignant lymphorna and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9: 17-24, 1991
130. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, Wittes RE, Jaffe ES, Steinberg SM, Herdt J, Chabner BA: Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 13: 1995-2004, 1995
131. Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE: A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 9: 135-140, 1998
132. Milroy R: A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. Br J Cancer 68: 813-818, 1993
133. Ross HJ, Cho J, Osann K, Wong SF, Ramsinghani N, Williams J, Downey-Hurtado N, Slater LM: Phase I/II trial of low dose cyclosporin A with EP for advanced non-small cell lung cancer. Lung Cancer 18: 189-198, 1997
134. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, Noone MR, Denicoff AM, Barnes CS, Gossard MR, Fetsch PA, Berg SL, Balis FM, Venzon DJ, O'Shaughnessy JA: Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14: 1173-1184, 1996
135. Wishart G, Bisset D, Paul J, Harnett JA, Habeshaw T, Kerr DJ, Macham MA, Soukop M, Leonard RCF, Knepil J, Kaye SB : Quinidine as a resitance modulator of epirubicin in advanced breast cancer: Mature results of a placebo-controlled randomized trial. J Clin Oncol 12: 1771-1777, 1994
136. Warner E, Heffley D, Andrulis I, Myers R, Trudeau M, Warr D, Pritchard KI, Blackstein M, Goss PE, Franssen E, Roche K, Knight S, Webster S, Fraser RA, Oldfield S, Hill W, Kates R: Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 4: 1451-1457, 1998
137. Verweij J, Herweijer H, Oosterom R, van der Burg MEL, Planting ASTh, Seynaeve C, Stoter G, Nooter K: A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. Br J Cancer 64: 361-364, 1991
138. Rodenburg CJ, Nooter K, Herweijer H, Seynaeve, Oosterom R, Stoter G, Verweij J: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2: 305-306, 1991
139. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 100: 2430-2436,1997
140. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 59: 1454-1457, 1999
141. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acrid inecarboxam ide derivative. Cancer Res 53: 4595-4602, 1993
142. Sparreboom A, Planting AST, Jewell RC, de Bruijn P, Loos WJ, Paul EM, Wissel PS, Nooter K, Stoter G, Verweij J: Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein. AntiCancer Drugs, in press
143. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM: Functional imaging of multi-drug resistant P-glycoprotein with an organtechnetium complex. Cancer Res 53: 977-984, 1993
144. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfil C, Thomas R, D'Aiuto G, Tsuruo T, Salvatore M: Fractional retention of Technetium-99m-Sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38: 1348-1351, 1997
145. Chen CC, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, Bates SE: Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi. Clin Cancer Res 3: 545-552, 1997
146. Hendriks NH, Franssen EJF, van der Graaf WTA, Meijer C, Piers DA, Vaalburg W, de Vries EGE: 99m-Tc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 77: 353-358, 1998
147. Whitherspoon SM, Emerson DL, Kerr BM, Lloyd TL, Dalton WS, Wissel PS: Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918. Clin Cancer Res 2: 7-12, 1996
148. Robey R, Bakke S, Stein W, Meadows B, Litman T, Patil S, Smith T, Fojo T, Bates S: Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833. Blood 93: 306-314
149. Ruetz S, Brault M, Dalton W, Gros P: Functional interactions between synthetic alkyl phospholipids and the ABC transporters P-glycoprotein, Ste-6, MRP, and Pgh 1. Biochemistry 36: 8180-8188, 1997
150. Ringel I, Horwitz SB: Studies with RP 56976 (taxotere): a semisynthetic analogue of taxel. J Natl Cancer Inst 83: 288-291, 1991
151. Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524, 1996